BostonGene
Founded Year
2015Stage
Series B | AliveTotal Raised
$200MValuation
$0000Last Raised
$150M | 1 yr agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+20 points in the past 30 days
About BostonGene
BostonGene uses biomedical software for advanced patient analysis and personalized therapeutic decision-making in the fight against cancer. BostonGene's solution performs sophisticated analyses to assist physicians in evaluating viable treatment options for each patient's individual genetics, tumor microenvironment and tumor, clinical characteristics, and disease profile. BostonGene's seeks to enable physicians to provide all patients with the highest likelihood of survival through optimal cancer treatments using advanced and personalized therapies. The company was founded in 2015 and is based in Waltham, Massachusetts.
Missing: BostonGene's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BostonGene's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing BostonGene
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BostonGene in 1 CB Insights research brief, most recently on Jul 7, 2022.
Expert Collections containing BostonGene
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BostonGene is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,214 items
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Digital Health
10,338 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Health IT
7,901 items
BostonGene Patents
BostonGene has filed 46 patents.
The 3 most popular patent topics include:
- Molecular biology
- Oncology
- Genomics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/29/2022 | 2/21/2023 | Transcription factors, Cell biology, Clusters of differentiation, Immunology, Oncology | Grant |
Application Date | 3/29/2022 |
|---|---|
Grant Date | 2/21/2023 |
Title | |
Related Topics | Transcription factors, Cell biology, Clusters of differentiation, Immunology, Oncology |
Status | Grant |
Latest BostonGene News
May 23, 2023
Save for later NEW YORK – BostonGene on Tuesday announced a precision oncology partnership with the University of Miami Sylvester Comprehensive Cancer Center focused on high-grade B-cell lymphoma patients. For its part of the collaboration, Waltham, Massachusetts-based BostonGene will perform next-generation sequencing, whole exome sequencing, and whole transcriptome analyses on high-grade B-cell lymphoma (HGBCL) tumor samples collected at Sylvester. BostonGene will then use its computational platform to home in on somatic alterations and gene expression, shedding light on the genomic and transcriptomic profiles to assess patients' tumor microenvironment activity. In classifying patients' tumor heterogeneity and microenvironment, the ultimate goal is for the partnership to help guide treatment strategies and improve outcomes among HGBCL patients. "We firmly believe that our next-generation multi-platform analytics will reveal distinct characteristics that can be utilized to personalize treatment," BostonGene Chief Medical Officer Nathan Fowler said in a statement.
BostonGene Frequently Asked Questions (FAQ)
When was BostonGene founded?
BostonGene was founded in 2015.
Where is BostonGene's headquarters?
BostonGene's headquarters is located at University Office Park III, Waltham.
What is BostonGene's latest funding round?
BostonGene's latest funding round is Series B.
How much did BostonGene raise?
BostonGene raised a total of $200M.
Who are the investors of BostonGene?
Investors of BostonGene include NEC, Japan Industrial Partners and Impact Investment Capital.
Who are BostonGene's competitors?
Competitors of BostonGene include Pangea Biomed.
Compare BostonGene to Competitors
Caris provides artificial intelligence integrated molecular science technology that assesses deoxyribonucleic acid, Ribonucleic acid, and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make personalized treatment decisions. It also researches and develops molecular profiling of blood and tissues. The company was founded in 2008 and is based in Irving, Texas.
GeneCentric focuses on the development and commercialization of molecular diagnostic assays that enable oncologists and patients to make more informed, individualized treatment decisions. GeneCentric was formerly known as GeneCentric Diagnostics. The company was founded in 2011 and is based in Durham, North Carolina.
Strata Oncology is a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and a portfolio of matching clinical trials.
Genialis builds software to empower scientists to find meaning in their data. Its Platform is a B2B enterprise web software for high-throughput biological data management, analysis, visualization, and collaboration. The company was founded in 2013 and is based in Boston, Massachusetts.
DarwinHealth is a precision-focused cancer medicine company that has developed, owns, and utilizes proprietary algorithms and methodologies to match virtually every individual cancer patient – at every stage of their disease – with those drugs and drug combinations that are optimally suited to produce successful treatment outcomes.
Pangea Biomed develops a multi-cancer and multi-therapy response predictor. It combines machine learning and deep RNA (Ribonucleic Acid) analysis to map tumor molecular signatures for personalized cancer care. The company aims to bring precision oncology to cancer patients for the improvement of oncology drug development, and the empowerment of oncologists to treat patients. Pangea Biomed was founded in 2018 and is based in Tel Aviv, Israel.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.